JS 111
Alternative Names: AP-L1898 Capsules; APL-1898; JS-111Latest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator Wigen Biomedicine
- Developer Suzhou Junjing BioSciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 13 Jul 2021 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT04993391)
- 23 Feb 2021 NMPA accepts IND for JS 111 in non small cell lung cancer for review
- 23 Feb 2021 NMPA approves JS 111 to conduct clinical trials for non-small cell lung cancer in China